EMERGENT BIOSOLUTIONS INC. (EBS) Debt Components
- 2026-06-30: Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $581.80M; Long-term DebtUSD $589.70M.
- 2026-03-31: Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $573.60M; Long-term DebtUSD $589.70M.
- 2025-12-31: Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $572.10M; Long-term DebtUSD $589.70M.
- 2025-12-31: Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m).
EMERGENT BIOSOLUTIONS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Line of Credit Facility, Current Borrowing Capacity USD | Long-term Debt, Fair Value USD | Debt Instrument, Interest Rate, Stated Percentage pure |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $581.80M | $589.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $573.60M | $589.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $572.10M | $589.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | $0.00 | $0.00 | $589.70M | $0.00 | $0.00 | $0.00 | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $663.10M | $693.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $667.80M | $700.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $665.70M | $700.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $663.70M | $700.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $0.00 | (m) | (m) | $0.00 | $0.00 | $0.00 | $700.00M | $0.00 | $0.00 | (m) | (m) | (m) |
| 2024-09-30 | $800.00K | $800.00K | $661.80M | $700.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $415.20M | $415.20M | $447.00M | $863.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $459.20M | $459.20M | $446.70M | $909.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $413.70M | $413.70M | $446.50M | $868.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | $418.40M | $0.00 | $0.00 | $0.00 | $450.00M | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | $413.60M | $413.60M | $448.20M | $866.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $455.20M | $455.20M | $448.00M | $909.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $950.70M | $950.70M | $447.70M | $1.41B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $957.30M | $957.30M | $448.50M | $1.41B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | $961.50M | $300.00K | $0.00 | $2.00M | $450.00M | $0.00 | (m) | (m) | (m) |
| 2022-09-30 | $21.20M | (m) | $1.03B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $21.20M | (m) | $1.06B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $31.60M | $31.60M | $793.60M | $832.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $31.60M | $31.60M | $801.50M | $841.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $31.60M | $31.60M | $809.40M | $849.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $33.80M | $363.60M | $200.00K | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $31.60M | $31.60M | $817.30M | $858.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $28.80M | $28.80M | $825.20M | $863.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $26.00M | $26.00M | $833.10M | $869.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $33.80M | $33.80M | $841.00M | $885.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | $35.90M | $33.80M | $363.60M | $200.00K | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $30.90M | $30.90M | $848.50M | $891.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $29.10M | $29.10M | $758.10M | $796.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $26.30M | $26.30M | $762.90M | $799.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $12.90M | $12.90M | $798.40M | $822.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $14.10M | $35.90M | $33.70M | $735.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $10.10M | $813.30M | $835.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $10.10M | $830.40M | $853.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $10.10M | $732.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $10.10M | $10.10M | $784.50M | $808.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $11.30M | $14.10M | $35.90M | $33.80M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $13.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $13.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $13.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $0.00 | $13.50M | $13.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 2.88% |
| 2017-09-30 | $0.00 | (m) | $248.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $200.00M | (m) | (m) |
| 2017-06-30 | $0.00 | (m) | $248.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $0.00 | (m) | $248.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $20.00M | (m) | $248.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $20.00M | (m) | $247.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $247.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $247.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | (m) | $246.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $253.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $253.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $251.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $251.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $251.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $251.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $251.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $62.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | $62.00M | $0.00 | $0.00 | $0.00 | $0.00 | $62.00M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $4.47M | $54.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $4.47M | $56.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $4.47M | $57.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $4.47M | $58.30M | $62.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $4.47M | $23.07M | $2.61M | $2.61M | $30.02M | (m) | (m) | $62.80M | (m) |
| 2012-09-30 | (m) | $4.15M | $58.87M | $63.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $63.01M | (m) |
| 2012-06-30 | (m) | $4.06M | $58.14M | $62.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $62.20M | (m) |
| 2012-03-31 | (m) | (m) | $57.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $5.36M | $54.09M | $59.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $59.50M | (m) |
| 2011-09-30 | (m) | $4.92M | $48.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $10.23M | $29.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $30.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $17.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |